Literature DB >> 9605290

The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females.

M Zatz1, S K Marie, A Cerqueira, M Vainzof, R C Pavanello, M R Passos-Bueno.   

Abstract

We investigated 52 families of patients with facioscapulohumeral muscular dystrophy (FSHD1), including 172 patients (104 males and 68 females). Among 273 DNA samples which were analyzed with probe p13E-11, 131 (67 males and 64 females) were shown to carry an EcoRI fragment smaller than 35 kb; 114 among them were examined clinically and neurologically. Results of the present investigation showed that: a) there is no molecular evidence for autosomal or X-linked recessive inheritance of FSHD1; b) an excess of affected males, which is explained by a significantly greater proportion of females than males among asymptomatic cases and a significantly greater proportion of affected sons than daughters observed in the offspring of asymptomatic mothers; c) the penetrance of the FSHD1 gene until age 30 was estimated as 83% for both sexes but was significantly greater for males (95%) than for females (69%); d) new mutations occur significantly more frequently in females than males among somatic/germinal mosaic cases; and e) severely affected cases originated more often through new mutations or were transmitted through maternal than through paternal lines including somatic/germinal mothers. These observations have important implications for understanding the molecular mechanisms responsible for FSHD1 and for genetic and prognostic counseling according to the gender of the affected patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605290

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  41 in total

1.  De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10.

Authors:  S M van der Maarel; G Deidda; R J Lemmers; P G van Overveld; M van der Wielen; J E Hewitt; L Sandkuijl; B Bakker; G J van Ommen; G W Padberg; R R Frants
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Petra G M Van Overveld; Lodewijk A Sandkuijl; Harry Vrieling; George W Padberg; Rune R Frants; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

3.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

4.  Clinical features of facioscapulohumeral muscular dystrophy 2.

Authors:  J C de Greef; R J L F Lemmers; P Camaño; J W Day; S Sacconi; M Dunand; B G M van Engelen; S Kiuru-Enari; G W Padberg; A L Rosa; C Desnuelle; S Spuler; M Tarnopolsky; S L Venance; R R Frants; S M van der Maarel; R Tawil
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

Review 5.  The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy.

Authors:  Silvère M van der Maarel; Rune R Frants
Journal:  Am J Hum Genet       Date:  2005-01-24       Impact factor: 11.025

6.  Equal proportions of affected cells in muscle and blood of a mosaic carrier of facioscapulohumeral muscular dystrophy.

Authors:  Maria Manuela O Tonini; Richard J L F Lemmers; Rita C M Pavanello; Antonia M P Cerqueira; Rune R Frants; Silvere M van der Maarel; Mayana Zatz
Journal:  Hum Genet       Date:  2005-12-08       Impact factor: 4.132

7.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Authors:  Emanuela Teveroni; Marsha Pellegrino; Sabrina Sacconi; Patrizia Calandra; Isabella Cascino; Stefano Farioli-Vecchioli; Angela Puma; Matteo Garibaldi; Roberta Morosetti; Giorgio Tasca; Enzo Ricci; Carlo Pietro Trevisan; Giuliana Galluzzi; Alfredo Pontecorvi; Marco Crescenzi; Giancarlo Deidda; Fabiola Moretti
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

8.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

9.  Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.

Authors:  Mirjam Larsen; Simone Rost; Nady El Hajj; Andreas Ferbert; Marcus Deschauer; Maggie C Walter; Benedikt Schoser; Pawel Tacik; Wolfram Kress; Clemens R Müller
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

Review 10.  The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.

Authors:  Daphne Selvaggia Cabianca; Davide Gabellini
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.